Atamyo Therapeutics

Our mission: to bring a new generation of best-in-class gene therapies to patients suffering from neuromuscular diseases.

[Atamyo Therapeutics @AtamyoTX]

In honor of LGMD Awareness day, @atamyoTX announces key milestones in our #genetherapy for #LGMD. Read the full release: https://t.co/QV9PYjOLFP

[Atamyo Therapeutics @AtamyoTX]

@AtamyoTX is proud to announce this new partnership with The Dion Foundation to expand our first-in-human trial of ATA-200 #genetherapy to treat LGMD2C/R5 in the US. Read full press release here: https://t.co/X9CCx5tfzv #LGMD #MuscularDystrophy

[Atamyo Therapeutics @AtamyoTX]

@EUeic @EU_Commission @Ili_Ivanova @EUScienceInnov @EU_Growth @HorizonEU @DigitalEU @EU_EISMEA @Access2EIC Thrilled to be selected for a ~#EICaccelerator blended grant+equity financing !

[Atamyo Therapeutics @AtamyoTX]

Atamyo Therapeutics Obtains US FDA Fast Track Designation  for ATA-100, a Gene Therapy in Phase 1/2 Clinical Trials for Limb-Girdle Muscular Dystrophy Type R9 (LGMD-R9) https://t.co/yTp4otcTEe

[CGTLive® @CGT_Live]

ICYMI:

The trial, which will take the form of a dose escalation study, is expected to enroll 6 participants in total.

#MuscularDystrophy #genetherapy #LimbGirdleMuscularDystrophy @AtamyoTX

Read more:

https://t.co/LGEYiNgi35

[Atamyo Therapeutics @AtamyoTX]

@atamyotx #LGMD programs featured in scientific presentations at #Myology2024. #genetherapy Details: https://t.co/7vAsY6cDsl . .

[Atamyo Therapeutics @AtamyoTX]

@AtamyoTX approved to initiate #clinicaltrial of ATA-200 in France and Italy. ATA-200 single-injection #genetherapy aimed to treat LGMD2C/R5 caused by mutations in the g-sarcoglycan gene. Ph1b study to evaluate safety and efficacy in children. https://t.co/KtFWw3znuq
#LGMD

[Atamyo Therapeutics @AtamyoTX]

Atamyo Therapeutics Obtains Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-200, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5 - https://t.co/nFwj0LsV1L

[Atamyo Therapeutics @AtamyoTX]

Atamyo Therapeutics' CEO, Stephane Degove, will present Atamyo's progress at the forthcoming 17th Annual European Life Sciences CEO Forum (#Sachs_ELSF) in Zurich, on 28th February at 12:20 (Room Berne). Looking forward to meeting the Finance and Biotech/Pharma community.

[Atamyo Therapeutics @AtamyoTX]

First results of ATA-100 in Ph1b/2b clinical trial presented at #ESGCT23. ATA-100 is one-time #genetherapy for FKRP LGMD2I/R9. Also announced, DSMB authorized enrollment of 2nd dose cohort of the ATA-001 #clinicaltrials #LGMB #musculardystrophy
https://t.co/cVHKx6zclb

[Atamyo Therapeutics @AtamyoTX]

@AtamyoTX stands by the #LGMD Community and reiterates its full commitment to develop treatments for LGMD and to better describe how this disease affects patients' lives. #LgmdAwareness #genetherapy

[Atamyo Therapeutics @AtamyoTX]

@AtamyTX and our #LGMD #genetherapy programs will be represented at October conferences across the US and in EU. See you there. #musculardystrophy
Details: https://t.co/rZAM3cNJAP

[Atamyo Therapeutics @AtamyoTX]

Another key milestone reached for @AtamyoTX and for the #LGMD community, this time with a potential one-time treatment for the devastating LGMD2C/R5 disease. #genetherapy #musculardystrophy

[Atamyo Therapeutics @AtamyoTX]

@AtamyoTX announces @US_FDA cleared its IND for ATA-100  to proceed in a Phase 1b/2b #ClinicalTrials. ATA-100 is one-time #genetherapy for treatment of fukutin-related protein (FKRB) #LGMD Type 2I/R9. #musculardystrophy  Details: https://t.co/QmFxIa08MU

[Atamyo Therapeutics @AtamyoTX]

@atamyotx announces appointment of Roger Hajjar, MD, Dir of the Gene and Cell Therapy Institute of @MassGenBrigham to it’s Board of Directors. Dr. Hajjar is a gene therapy pioneer and internationally recognized scientist. https://t.co/jFs1Rb1Fmx #genetherapy #LGMD

[Atamyo Therapeutics @AtamyoTX]

#CGMed23 tomorrow at 4PM @AtamyoTX company update by CEO Stephane Degove. Hope to see you there. #GeneTherapy

[Atamyo Therapeutics @AtamyoTX]

@atamyotx will be at #MeetingontheMed in Barcelona to present a company overview. Atamyo’s most advanced programs address different forms of #LGMD, with a clinical-stage program targeting LGMD-R9.#CellandGene #CGMed23

[Atamyo Therapeutics @AtamyoTX]

@atamyotx will be at #MeetingontheMed in Barcelona to present a company overview. Atamyo’s most advanced programs address different forms of #LGMD, with a clinical-stage program targeting LGMD-R9.#CellandGene #CGMed23

[Atamyo Therapeutics @AtamyoTX]

It's #LGMD Awareness Day!
@AtamyoTX
Isabelle Richard and her team have been working on LGMDs for over 30 years. One #GeneTherapy product is currently in trial for #FKRP LGMD. A trial conducted by
@AtamyoTX. Proud to develop treatments for this devastating disease

[GENETHON France @GenethonFr]

It's #LGMD Awareness Day! @GenethonFr , Isabelle Richard and her team have been working on LGMDs for over 30 years. One #GeneTherapy product is currently in trial for #FKRP LGMD. A trial conducted by @AtamyoTX , a Genethon spin-off

👉https://t.co/Z0Xskx5ipa